Metra Biosystems expecting to net $30.1 mil. in IPO.
This article was originally published in The Gray Sheet
Executive Summary
METRA BIOSYSTEMS' PYRILINKS(II) AND PYRILINKS-D 510(K)s were submitted on May 30 and May 17, respectively, giving the firm three pending 510(k)s for bone resorption assays. According to a recent filing with the Securities and Exchange Commission for an initial public offering, the Mountain View, California-based firm submitted a reworked 510(k) in April for its first bone resorption immunoassay, Pyrilinks, and plans to submit in early June a 510(k) for a fourth product, the Alkaphase-B bone formation assay.
You may also be interested in...
Deal Watch: AbbVie Teams With MedinCell On Long-Acting Injectables
Collaboration Edition: Including deals involving Evotec/Variant, Sanofi/IGM/Nurix, ABVC/OncoX and Harmony/Bioprojet, along with tech transfer agreements and deals in brief.
GE HealthCare Launches AI-Powered Voluson Ultrasound For Women’s Health
Voluson Signature 20 and 18 ultrasound provides clinicians with workflow efficiencies in detecting female reproductive health problems, especially those related to pregnancy.
CDER, CBER Not Seeing Hiring Slowdown Despite US FDA Warnings
FDA officials have said hiring could be slowed if an inflationary pay increase is not included in the agency budget, but CDER and CBER continue to add staff at a steady pace.